Comparative Pharmacology
Head-to-head clinical analysis: CHLORMERODRIN HG 197 versus SODIUM CHROMATE CR 51.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORMERODRIN HG 197 versus SODIUM CHROMATE CR 51.
CHLORMERODRIN HG 197 vs SODIUM CHROMATE CR 51
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radioactive mercury isotope that emits gamma rays; distributes in renal parenchyma, allowing scintigraphic imaging of kidneys. The mercury moiety binds to sulfhydryl groups in renal tubules, concentrating in functioning renal tissue.
Radiolabeled sodium chromate (51Cr) binds to red blood cells, tagging them for survival studies. 51Cr emits gamma radiation, allowing detection and quantification of RBC mass and survival via scintillation counting or imaging.
Chlormerodrin Hg 197 is administered intravenously as a single dose of 10 µCi (0.37 MBq) for renal imaging. The typical adult dose is 10-30 µCi (0.37-1.11 MBq) IV.
Intravenous injection, 5-30 microcuries (0.185-1.11 MBq) as a single dose.
None Documented
None Documented
Terminal elimination half-life approximately 3 days (72 hours) in patients with normal renal function; prolonged in renal impairment.
The biological half-life is approximately 27–30 days. Clinically, gradual clearance from blood and tissues occurs over weeks to months.
Renal: >90% of absorbed dose excreted in urine within 24 hours; biliary/fecal: <5%.
Primarily renal. Approximately 90% of absorbed dose is excreted in urine within 48 hours. Fecal excretion accounts for less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical